As per the recently published report by MarketsandMarkets™, The report "Preimplantation Genetic Testing Market by Procedure (Diagnosis, Screening), Technology (NGS, PCR, FISH, CGH, SNP), Product (Consumable, Instrument), Application (Aneuploid, HLA Typing), Type of Cycle, End User, and Region - Global Forecast to 2028", is projected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at a CAGR of 11.4% during the forecast period.
Download
PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Browse
- 182 Market Data Tables
- 44 Figures
- 245 Pages and in-depth TOC on "Preimplantation
Genetic Testing Market - Global Forecast to 2028”
Some of the prominent key players are:
- Illumina, Inc. (US),
- Thermo Fisher Scientific Inc. (US),
- Agilent Technologies, Inc. (US),
- Revvity (US),
- The Cooper Companies, Inc. (US), and many
more......
Mergers & acquisitions, investments & expansions,
partnerships & collaborations, and new product developments are some of the
major strategies adopted by these key players to enhance their positions in
the Preimplantation Genetic Testing Market.
Growth
DRIVER: Declining fertility rate
Global
fertility rates are observing a decline across a majority of the developed and
several developing countries, owing to various factors such as increased
maternal age of conceiving, low sperm count & motility, and hormonal
imbalance, thereby leading to higher demand for IVF procedures. Moreover, with
growing public awareness about the effective role of genetic techniques in the
risk assessment of genetic disorders, the adoption of preimplantation genetic
testing procedures is expected to grow during the forecast period. According to
the World Health Organization (WHO), in 2020, approximately 8 million couples
and 186 million individuals lived with infertility.
OPPORTUNITY:
Use of fertility treatment options by single parents and same-sex couples
Regulations
legalizing same-sex marriages in various countries across the globe, including
Greenland, Ireland, Canada, South Africa, and the US, are further expected to
increase the adoption of fertility procedures. The laws that support the use of
IVF procedures by same-sex and single parents are as follows such as The New
South Wales Assisted Reproductive Technology Act 2007 permits all women,
regardless of marital status, to access assisted conception procedures in the
Australian state. On the other hand The Human Reproductive Technology Act 1991
allows all women (lesbian or single) to access donor insemination in Western
Australia.
Market Segmentation:
- Preimplantation genetic screening, or
aneuploidy screening, involves screening embryos for the assessment of
aneuploidy. This segment is expected to dominate the global
preimplantation genetic testing market during the forecast period, driven
by a decrease in female fertility with rising maternal age, better
implantation rate and reduced IVF cycle times.
- Based on the products, the global
preimplantation genetic testing market is broadly segmented into
instruments, reagents & consumables, and software & services. The
expanding applications of specific technologies (such as NGS and aCGH for
whole-genome sequencing and FISH in the diagnosis of specific genetic
disorders).
- By end user, the global preimplantation
genetic testing market is broadly segmented into hospitals, diagnostic
labs, fertility clinics, and other end users. The large share of this
segment can be attributed to factors such as the increasing number of fertility
centers globally, the high success rate of treatment in fertility centers,
and growing medical tourism in developing countries.
- Based on the region, the preimplantation
genetic testing market is segmented into North America, Europe, Asia
Pacific, and the Rest of the World. The North American market is driven by
high incidence of chromosomal disorders, and an increasing number of awareness
programs.
Recent
Developments of Preimplantation Genetic Testing Industry:
- In 2023, Thermo Fisher Scientific Inc.
(US) launched two new NGS-based test kits to support preimplantation
genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization
(IVF) and intracytoplasmic sperm injection (ICSI) research.
- In 2022, The Cooper Companies, Inc. (US)
released the addition of Parental QC, Genetic PN check, and Origin of
Aneuploidy to PGT-A testing as PGT-Complete.
- In 2021, Vitrolife (Sweden) acquired
Igenomix (Spain), a leader in reproductive genetic testing services
primarily for IVF clinics.
The new research study consists of industry
trends, pricing analysis, patent analysis, conference and webinar materials,
key stakeholders, and buying behaviour in the market. The growth in this market
is attributed to the increasing demand for assisted reproductive technologies,
rising maternal age trends, and ongoing research and development in the field
of genetics. On the other hand, socio-ethical concerns surrounding
preimplantation genetic testing may challenge the growth of the market. Whereas
use of fertility treatment options by single parents and same-sex couples
provides growth opportunities for market.
Related News:
No comments:
Post a Comment